Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Beholder  – Russia, 2019-11-19 15:39 (2053 d 07:44 ago) – Posting: # 20828
Views: 8,870

❝ We don't know nothing about new FDC - no safety, no efficacy data. This is new drug.


Why no safety and efficacy data!? Lets take abovementioned examples:

Amlodipine + Indapamide + Perindopril - here
Losartan + Amlodipine + Rosuvastatin - here.
Indapamide + Rosuvastatin + Perindopril here.

So, can we say that "In all cases, the established regime has a well-characterized safety and efficacy profile..." and proceed with Scenario 2 comparing triple combination with two reference drugs?!
—
Best regards
Beholder

Complete thread:

UA Flag
Activity
 Admin contact
23,426 posts in 4,929 threads, 1,682 registered users;
48 visitors (0 registered, 48 guests [including 38 identified bots]).
Forum time: 00:23 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5